Vertex reaches CF deal in Scotland

After more than three years of negotiations, Vertex and Scotland have agreed to a five-year reimbursement agreement that gives cystic fibrosis patients access to two CF drugs, making Scotland the first in the U.K. to expand access to the drugs to all eligible patients.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced Thursday

Read the full 494 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE